Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 1,670 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Comparator Clear all
Active, not recruiting Phase 3 Interventional

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

NCT06719141
View directory record Official record
Conditions
Developmental and Epileptic Encephalopathy
Interventions
LP352, Placebo
Drug
Lead sponsor
Longboard Pharmaceuticals
Industry
Eligibility
2 Years to 65 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
31
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 25, 2026, 4:38 AM EDT
Completed Not applicable Interventional Results available

Preventing Overdose Using Information and Data From the Environment

NCT05096429
View directory record Official record
Conditions
Opioid Overdose, Drug Overdose
Interventions
PROVIDENT
Behavioral
Lead sponsor
Brown University
Other
Eligibility
Not listed
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 25, 2026, 4:38 AM EDT
Completed Not applicable Interventional

Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema

NCT00475007
View directory record Official record
Conditions
Emphysema, COPD
Interventions
IBV® Valve System
Device
Lead sponsor
Olympus Corporation of the Americas
Industry
Eligibility
40 Years to 74 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
34
States / cities
Birmingham, Alabama • Los Angeles, California • Mission Viejo, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 25, 2026, 4:38 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of V132 in Healthy Older Participants (V132-001)

NCT07712575
View directory record Official record
Conditions
Healthy
Interventions
V132 Formulation 1, V132 Formulation 2, V132 Formulation 3, PREVNAR 20™, CAPVAXIVE™
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years to 75 Years
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
10
States / cities
Anaheim, California • Hallandale, Florida • Hollywood, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 25, 2026, 4:38 AM EDT
Completed Phase 1 Interventional

Trial to Assess the Potency of SOR007 Ointment in a Psoriasis Plaque Test

NCT03004339
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
SOR007 Ointment 2.0%, SOR007 Ointment 1.0%, SOR007 Ointment 0.3%, SOR007 Ointment 0.15%, SOR007 Ointment Placebo, Taclonex® Ointment
Drug
Lead sponsor
DFB Soria, LLC
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Austin, Texas • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 25, 2026, 4:38 AM EDT
Completed Phase 1 Interventional

Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM

NCT01708044
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Pramlintide acetate, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Oct 25, 2026, 4:38 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years

NCT02434276
View directory record Official record
Conditions
Influenza
Interventions
VAX2012Q, Fluzone Quadrivalent
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 64 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
6
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 25, 2026, 4:38 AM EDT
Active, not recruiting Phase 2 Interventional

Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder

NCT02839915
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Folinic Acid, Placebo
Drug · Other
Lead sponsor
Southwest Autism Research & Resource Center
Other
Eligibility
5 Years to 17 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Phoenix, Arizona • Atlanta, Georgia • Lexington, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 25, 2026, 4:38 AM EDT
Completed Phase 2 Interventional Results available

A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)

NCT03086460
View directory record Official record
Conditions
Asthma
Interventions
CHF 1531 pMDI, Formoterol Inhalation Solution, Placebo pMDI
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Tucson, Arizona • Los Angeles, California • Lutherville, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Oct 25, 2026, 4:38 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease

NCT02060526
View directory record Official record
Conditions
Sanfilippo Syndrome
Interventions
Recombinant human heparan N-sulfatase [rhHNS]
Drug
Lead sponsor
Shire
Industry
Eligibility
12 Months to 48 Months
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Torrance, California • Minneapolis, Minnesota • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 25, 2026, 4:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers

NCT02743455
View directory record Official record
Conditions
Yellow Fever, Yellow Fever Immunisation
Interventions
ISA-720, MVA Smallpox Vaccine, MVA-BN Yellow Fever Vaccine, Placebo, YF Vax 17D Strain
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Iowa City, Iowa • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 25, 2026, 4:38 AM EDT
Completed Phase 3 Interventional

Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks

NCT00240617
View directory record Official record
Conditions
Migraine Disorders
Interventions
sumatriptan succinate/naproxen sodium, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
52
States / cities
Anniston, Alabama • Tuscaloosa, Alabama • Mesa, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 25, 2026, 4:38 AM EDT
Active, not recruiting Phase 2 Interventional

Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

NCT06046222
View directory record Official record
Conditions
Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
Interventions
NS-229, Placebo
Drug
Lead sponsor
NS Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Denver, Colorado • Rochester, Minnesota • Cleveland, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 25, 2026, 4:38 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

NCT06220604
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
JNJ-77242113, JNJ-77242113 Matching Placebo, Deucravacitinib, Deucravacitinib Matching Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
37
States / cities
Phoenix, Arizona • Encinitas, California • Encino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 4:38 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

QT-Digital Mental Health Engagement Study

NCT07278765
View directory record Official record
Conditions
Engagement, Patient
Interventions
HAPA Engagement Strategies
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
14 Years and older
Enrollment
2,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Alexandria, Virginia • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 25, 2026, 4:38 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)

NCT07300267
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
V118C (Stage 1), V118C (Stage 2), PCV20 (Stage 1), PCV20 (Stage 2)
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Months to 15 Months
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
15
States / cities
Madera, California • Miami, Florida • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 25, 2026, 4:38 AM EDT
Completed Not applicable Interventional Results available

D-CARE - The Dementia Care Study: A Pragmatic Clinical Trial of Health System-Based Versus Community-Based Dementia Care

NCT03786471
View directory record Official record
Conditions
Dementia
Interventions
Health System-based Dementia Care, Community-based Dementia Care, Usual Care
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Enrollment
2,176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Winston-Salem, North Carolina • Wilkes-Barre, Pennsylvania • Galveston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 25, 2026, 4:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Psychophysiologic Predictors of Post-deployment Mental Health Outcomes

NCT00838006
View directory record Official record
Conditions
Post-traumatic Stress Disorder
Interventions
heart rate variability biofeedback, Cognitive bias modification training, Sham Comparator
Device
Lead sponsor
Biomedical Research Foundation
Other
Eligibility
18 Years to 60 Years
Enrollment
426 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Blackstone, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 2, 2020 · Synced Oct 25, 2026, 4:38 AM EDT
Completed Not applicable Interventional

SDRM® vs. Collagen for Diabetic Foot Ulcers

NCT05883098
View directory record Official record
Conditions
Diabetic Foot, Ulcer Foot, Wound Heal
Interventions
Wound debridement, Wound closure matrix application
Procedure · Device
Lead sponsor
Polymedics Innovations Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Circleville, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 25, 2026, 4:38 AM EDT
Completed Not applicable Interventional

Patient-Centered Physical Activity Program for Hemodialysis Patients

NCT07080593
View directory record Official record
Conditions
Hemodialysis
Interventions
Novel Physical Activity Program, Standard of Care Physical Activity Program
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
Bolingbrook, Illinois • Oak Brook, Illinois • Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 25, 2026, 4:38 AM EDT
Completed Phase 3 Interventional Results available

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

NCT02814916
View directory record Official record
Conditions
Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
Interventions
Dalbavancin, Vancomycin, Oxacillin, Flucloxacillin, Cefadroxil, Clindamycin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
0 Years to 17 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
15
States / cities
Mobile, Alabama • Phoenix, Arizona • La Palma, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 25, 2026, 4:38 AM EDT
Recruiting Phase 3 Interventional

BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT07755904
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic Obstructive
Interventions
BHB-1893, Metoprolol
Drug
Lead sponsor
Braveheart Bio, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Manhasset, New York • Rock Hill, South Carolina • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 25, 2026, 4:38 AM EDT
Completed Not applicable Interventional

Fluoroscopy Guided Femoral Arterial Access

NCT00222430
View directory record Official record
Conditions
Vascular Access
Interventions
Fluoroscopy, Active Comparator
Procedure
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 28, 2012 · Synced Oct 25, 2026, 4:38 AM EDT
Completed Not applicable Interventional

Efficacy of Brief Acceptance and Commitment Therapy (ACT) for Perinatal Anxiety

NCT03837392
View directory record Official record
Conditions
Post Partum Depression, Perinatal Depression, Post Partum Anxiety, Perinatal Anxiety
Interventions
Baseline Assessment (18-26 weeks pregnant), Online Intervention and Phone Coaching Interventions, Follow Up Assessments: 34-36 weeks pregnant and 4-week postpartum, Follow Up Assessments: 8 weeks postpartum
Diagnostic Test · Behavioral
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 25, 2026, 4:38 AM EDT